Nasdaq Stockholm-listed Isofol Medical, which is developing the drug candidate arfolitixorin, has appointed Petter Segelman Lindqvist as its new CEO. He has extensive experience from leading roles in several international…
Sweden: Isofol appoints Petter Segelman Lindqvist as its new CEO
…
…






